Orforglipron, the first oral non-peptide GLP-1 receptor agonist, reduced HbA1c by up to 1.8% and body weight by up to 5.8 kg over 12 weeks in people with type 2 diabetes, with a side effect profile similar to injectable GLP-1 drugs.
Up to -1.8% HbA1c and -5.8 kgOrforglipron, the first non-peptide oral GLP-1 agonist, achieved clinically meaningful blood sugar and weight reductions over just 12 weeks in people with type 2 diabetes.
What the researchers found
Across multiple dosing regimens over 12 weeks, orforglipron produced mean HbA1c reductions of 1.5% to 1.8%, compared to 0.4% with placebo. Body weight changes ranged from -0.24 kg to -5.8 kg with orforglipron, versus +0.5 kg with placebo.
The drug had a half-life of 29-49 hours at Week 12, supporting once-daily dosing. Weekly dose escalation was shown to be generally well tolerated, providing guidance for future dosing protocols.
The most common adverse events were gastrointestinal-related and occurred early in treatment, consistent with the known class effects of GLP-1 receptor agonists. No new safety signals were identified beyond what is expected for this drug class.
Why it matters
All currently available GLP-1 receptor agonists are peptide-based, requiring either injection or special oral formulations with strict fasting rules. Orforglipron represents a potential paradigm shift — a simple daily pill that activates the GLP-1 receptor without being a peptide. If confirmed in larger trials, this could dramatically expand access to GLP-1 therapy for the hundreds of millions of people with type 2 diabetes worldwide who prefer oral medications over injections.
How the study worked
This was a Phase 1b, multicentre, double-blind, placebo-controlled, randomized, multiple-ascending-dose study. Five different dosing regimens were tested: the first group established tolerability with weekly dose escalation, followed by four parallel-arm groups. Participants (ages 18-70, HbA1c 7.0-10.5%) were randomized 3:1 to orforglipron or placebo for 12 weeks. Endpoints included safety, pharmacokinetics, HbA1c change, and body weight change.
What this study cannot tell us
This is a small Phase 1b study (68 participants) primarily designed for safety and pharmacokinetic assessment, not powered for definitive efficacy conclusions. The 12-week duration is short for assessing long-term metabolic outcomes and safety. The wide range in weight loss (-0.24 to -5.8 kg) across doses suggests dose-response optimization is still needed. No direct comparisons to injectable GLP-1 agonists were included. Long-term cardiovascular and renal outcomes are unknown.
How to read the evidence
This is a Phase 1b randomized, double-blind, placebo-controlled trial — early-stage clinical evidence with appropriate design. The small sample size (n=68) and short duration (12 weeks) limit conclusions, but the controlled design provides reliable preliminary data.
When this study was published
Published in 2023, this is early-phase clinical data for orforglipron. Larger Phase 2 and Phase 3 trials have since been conducted or are ongoing, building on these promising initial results.
The bigger picture
The development of non-peptide GLP-1 agonists represents a major evolution in the GLP-1 field. While peptide-based GLP-1 drugs like semaglutide have been enormously successful, their peptide nature creates manufacturing, stability, and delivery challenges. A small molecule that achieves similar effects could be cheaper to manufacture, easier to take, and more widely accessible — potentially democratizing a drug class that has transformed diabetes and obesity treatment.
Questions still open
- How does orforglipron compare head-to-head with injectable semaglutide for blood sugar control and weight loss?
- Will orforglipron achieve similar cardiovascular benefits as injectable GLP-1 agonists in outcome trials?
- Will the lower manufacturing complexity of a non-peptide drug translate to meaningfully lower costs for patients?
Common questions
How is orforglipron different from semaglutide (Ozempic/Wegovy)?
When might orforglipron become available to patients?
Read the original research
Orforglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist: A Phase 1b, multicentre, blinded, placebo-controlled, randomized, multiple-ascending-dose study in people with type 2 diabetes.
Diabetes, obesity & metabolism, 25(9), 2642-2649
Citation
Pratt, Edward; Ma, Xiaosu; Liu, Rong; Robins, Deborah; Coskun, Tamer; Sloop, Kyle W; Haupt, Axel; Benson, Charles. (2023). Orforglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist: A Phase 1b, multicentre, blinded, placebo-controlled, randomized, multiple-ascending-dose study in people with type 2 diabetes.. Diabetes, obesity & metabolism, 25(9), 2642-2649. https://doi.org/10.1111/dom.15150